Simulations Plus (SLP)
Market Price (5/11/2026): $16.5 | Market Cap: $332.6 MilSector: Health Care | Industry: Health Care Technology
Simulations Plus (SLP)
Market Price (5/11/2026): $16.5Market Cap: $332.6 MilSector: Health CareIndustry: Health Care Technology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% Attractive yieldFCF Yield is 6.2% Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. | Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -140% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% Key risksSLP key risks include [1] securities lawsuits, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -12% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 30%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 26% |
| Attractive yieldFCF Yield is 6.2% |
| Megatrend and thematic driversMegatrends include Artificial Intelligence, and Precision Medicine. Themes include AI Software Platforms, Biopharmaceutical R&D, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -109%, 3Y Excs Rtn is -140% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 34x |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -23% |
| Key risksSLP key risks include [1] securities lawsuits, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Simulations Plus (SLP) stock has remained largely at the same level since 1/31/2026 because of the following key factors:
1. Q1 Fiscal 2026 Earnings Miss: Simulations Plus reported adjusted earnings per share (EPS) of $0.17 for the first quarter of fiscal 2026 on January 8, 2026, missing analysts' expectations of $0.19 by 10.53%. This initial financial underperformance likely contributed to a negative sentiment at the beginning of the specified period.
2. Revised Fiscal Year 2026 Guidance and Increased Tax Rate: Despite beating Q2 fiscal 2026 EPS estimates with $0.35 against an expected $0.29, reported on April 9, 2026, Simulations Plus revised its fiscal year 2026 adjusted diluted EPS outlook. Concurrently, the company increased its expected effective tax rate for fiscal 2026 to between 23% and 25% from a previous expectation of 12% to 14%, a change that is anticipated to reduce near-term cash tax benefits. This updated guidance, especially the higher tax rate, likely pressured the stock.
Show more
1. Q1 Fiscal 2026 Earnings Miss: Simulations Plus reported adjusted earnings per share (EPS) of $0.17 for the first quarter of fiscal 2026 on January 8, 2026, missing analysts' expectations of $0.19 by 10.53%. This initial financial underperformance likely contributed to a negative sentiment at the beginning of the specified period.
2. Revised Fiscal Year 2026 Guidance and Increased Tax Rate: Despite beating Q2 fiscal 2026 EPS estimates with $0.35 against an expected $0.29, reported on April 9, 2026, Simulations Plus revised its fiscal year 2026 adjusted diluted EPS outlook. Concurrently, the company increased its expected effective tax rate for fiscal 2026 to between 23% and 25% from a previous expectation of 12% to 14%, a change that is anticipated to reduce near-term cash tax benefits. This updated guidance, especially the higher tax rate, likely pressured the stock.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -1.2% change in SLP stock from 1/31/2026 to 5/10/2026 was primarily driven by a -3.4% change in the company's P/S Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.89 | 16.68 | -1.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 79 | 81 | 2.4% |
| P/S Multiple | 4.3 | 4.2 | -3.4% |
| Shares Outstanding (Mil) | 20 | 20 | -0.1% |
| Cumulative Contribution | -1.2% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLP | -1.2% | |
| Market (SPY) | 3.6% | 44.3% |
| Sector (XLV) | -6.9% | 17.7% |
Fundamental Drivers
The -2.9% change in SLP stock from 10/31/2025 to 5/10/2026 was primarily driven by a -2.9% change in the company's P/S Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 17.18 | 16.68 | -2.9% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 80 | 81 | 0.2% |
| P/S Multiple | 4.3 | 4.2 | -2.9% |
| Shares Outstanding (Mil) | 20 | 20 | -0.2% |
| Cumulative Contribution | -2.9% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLP | -2.9% | |
| Market (SPY) | 5.5% | 32.4% |
| Sector (XLV) | 0.3% | 11.3% |
Fundamental Drivers
The -51.4% change in SLP stock from 4/30/2025 to 5/10/2026 was primarily driven by a -52.5% change in the company's P/S Multiple.| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 34.35 | 16.68 | -51.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 79 | 81 | 2.5% |
| P/S Multiple | 8.8 | 4.2 | -52.5% |
| Shares Outstanding (Mil) | 20 | 20 | -0.3% |
| Cumulative Contribution | -51.4% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLP | -51.4% | |
| Market (SPY) | 30.4% | 24.9% |
| Sector (XLV) | 4.0% | 19.5% |
Fundamental Drivers
The -59.8% change in SLP stock from 4/30/2023 to 5/10/2026 was primarily driven by a -72.7% change in the company's P/S Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 41.44 | 16.68 | -59.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 54 | 81 | 48.0% |
| P/S Multiple | 15.3 | 4.2 | -72.7% |
| Shares Outstanding (Mil) | 20 | 20 | -0.2% |
| Cumulative Contribution | -59.8% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| SLP | -59.8% | |
| Market (SPY) | 78.7% | 25.7% |
| Sector (XLV) | 13.0% | 21.0% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SLP Return | -34% | -22% | 23% | -37% | -35% | -12% | -77% |
| Peers Return | -30% | -50% | 23% | -34% | -9% | -22% | -80% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| SLP Win Rate | 33% | 33% | 50% | 42% | 50% | 40% | |
| Peers Win Rate | 42% | 35% | 54% | 36% | 45% | 32% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| SLP Max Drawdown | -48% | -23% | -8% | -39% | -55% | -38% | |
| Peers Max Drawdown | -35% | -58% | -23% | -46% | -21% | -32% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CERT, SDGR, SPCE, VEEV, SOLV. See SLP Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | SLP | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.4% | -9.5% |
| % Gain to Breakeven | 39.6% | 10.5% |
| Time to Breakeven | 161 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -26.4% | -24.5% |
| % Gain to Breakeven | 35.9% | 32.4% |
| Time to Breakeven | 36 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -30.6% | -33.7% |
| % Gain to Breakeven | 44.1% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -14.2% | -19.2% |
| % Gain to Breakeven | 16.6% | 23.7% |
| Time to Breakeven | 61 days | 105 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -13.8% | -6.8% |
| % Gain to Breakeven | 16.1% | 7.3% |
| Time to Breakeven | 71 days | 15 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -11.3% | -15.4% |
| % Gain to Breakeven | 12.7% | 18.2% |
| Time to Breakeven | 13 days | 125 days |
In The Past
Simulations Plus's stock fell -28.4% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 39.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | SLP | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -28.4% | -9.5% |
| % Gain to Breakeven | 39.6% | 10.5% |
| Time to Breakeven | 161 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -26.4% | -24.5% |
| % Gain to Breakeven | 35.9% | 32.4% |
| Time to Breakeven | 36 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -30.6% | -33.7% |
| % Gain to Breakeven | 44.1% | 50.9% |
| Time to Breakeven | 35 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -78.6% | -53.4% |
| % Gain to Breakeven | 366.6% | 114.4% |
| Time to Breakeven | 1091 days | 1085 days |
In The Past
Simulations Plus's stock fell -28.4% during the Summer-Fall 2023 Five Percent Yield Shock. Such a loss loss requires a 39.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Simulations Plus (SLP)
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through four segments: Simulations Plus, Cognigen, DILIsym, and Lixoft. The company offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, a quantitative systems pharmacology software; NAFLDsym; IPFsym; RENAsym; and MITOsym. In addition, the company provides Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as modeling and simulation products comprising MonolixSuite and PKPlus. Further, it provides population modeling and simulation contract research services; training and consulting services designed to accelerate pharmacometrics studies; and clinical-pharmacology-based consulting services in support of regulatory submissions. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
AI Analysis | Feedback
```htmlHere are 1-2 brief analogies to describe Simulations Plus (SLP):
- It's like Ansys, but for simulating how drugs behave in the human body and during development. (Ansys is well-known for its engineering simulation software; SLP provides specialized simulation tools for pharmaceutical and biotech R&D.)
- Think of it as MathWorks (MATLAB) for pharmaceutical R&D, focused on AI-powered predictive modeling. (MathWorks, known for MATLAB, provides powerful computational software for scientists and engineers; SLP offers highly specialized computational tools and services for drug discovery and development, leveraging AI and machine learning.)
AI Analysis | Feedback
- GastroPlus: Software that simulates the absorption and drug interaction of compounds administered to humans and animals.
- DDDPlus & MembranePlus: Simulation products used for drug discovery and development.
- DILIsym: Quantitative systems pharmacology software based on mechanistic and mathematical models.
- Other Mechanistic and Mathematical Model Software: Products like NAFLDsym, IPFsym, RENAsym, and MITOsym, which are based on mechanistic and mathematical models for various simulations.
- ADMET Predictor: A chemistry-based computer program that takes molecular structures as inputs and predicts their Absorption, Distribution, Metabolism, Excretion, and Toxicity properties.
- MedChem Designer: Software used for chemistry-based molecular design.
- MonolixSuite & PKPlus: Modeling and simulation products utilized in pharmacometrics studies.
- Population Modeling and Simulation Contract Research Services: Services designed to accelerate pharmacometrics studies through expert population modeling and simulation.
- Training and Consulting Services: Services providing education and guidance to accelerate pharmacometrics studies.
- Clinical-Pharmacology-Based Consulting Services: Specialized consulting services offered to support regulatory submissions.
AI Analysis | Feedback
Simulations Plus (SLP) sells its drug discovery and development software and services primarily to other companies and organizations. Its major customers fall into the following categories:
- Pharmaceutical companies
- Biotechnology companies
- Agrochemical companies
- Cosmetics companies
- Food companies
- Academic institutions
- Regulatory agencies
AI Analysis | Feedback
null
AI Analysis | Feedback
Shawn O'Connor, Chief Executive Officer
Shawn O'Connor brings over three decades of executive experience across various industries, including startups and publicly traded companies, with a focus on strategy definition, organizational development, and value creation for investors. Before joining Simulations Plus as CEO in June 2018, he served as president, chief executive officer, and director of Entelos, a company providing quantitative systems pharmacology software and services. Prior to Entelos, Mr. O'Connor was chairman, president, and chief executive officer of Pharsight Corporation, a developer and marketer of software products and services for drug development and commercialization. In this role, he implemented a software product strategy that led to significant revenue, gross profit, and cash flow improvements, increasing the company's valuation by 20 times. Mr. O'Connor also has experience as the CFO of Diasonics, Inc.
Will Frederick, Executive Vice President & Chief Financial Officer
Will Frederick joined Simulations Plus in December 2020 as Chief Financial Officer and Secretary and assumed the additional role of Chief Operating Officer in January 2024. He possesses more than 25 years of financial leadership experience, with a proven track record in developing strategies to drive revenue growth, enhance profitability, manage merger and acquisition activities, and achieve corporate objectives. His extensive global experience spans both publicly traded and privately held companies, including notable organizations such as Pharsight, Entelos, Avaya, The Walt Disney Company, and Ford Motor Company. Notably, Mr. Frederick served as CFO at Pharsight and Entelos during the periods when Shawn O'Connor was CEO, indicating a history of collaboration within the drug development software industry.
John A. DiBella, Chief Revenue Officer
John A. DiBella was appointed Chief Revenue Officer in May 2025, taking responsibility for all revenue-generating activities at Simulations Plus.
Josh Fohey, Chief Operating Officer
Josh Fohey oversees the day-to-day business operations for Simulations Plus. In January 2024, he transitioned from Vice President of Business Development to Senior Vice President, Operations. He joined Simulations Plus in 2019, initially as Director of Operations, and was promoted to Vice President, Operations in 2020. Before joining the company, Mr. Fohey spent 14 years at Covance, where he held various operational, scientific, and business development roles.
Viera Lukacova, Chief Science Officer
Viera Lukacova is responsible for ensuring the scientific precision of Simulations Plus's core software products.
AI Analysis | Feedback
The key risks to Simulations Plus (SLP) include challenges with integrating acquired companies, market uncertainties impacting client spending, and intense competition within its niche market.
- Acquisition Integration Challenges and Financial Reporting Concerns: Simulations Plus has faced significant hurdles in integrating acquired companies and technologies. In the third quarter of fiscal year 2025, the company reported a substantial non-cash impairment charge of $77.2 million related to prior acquisitions, which resulted in a net loss of $67.3 million for that quarter. This impairment charge specifically highlighted issues with the performance or integration of acquired assets, including those from the Pro-ficiency Holdings, Inc. acquisition, and raised concerns about the effectiveness of internal controls. Furthermore, investigations have been launched into whether the company may have misled investors regarding asset valuations and the dismissal of its independent auditor, Grant Thornton, who had expressed concerns about segment reporting and internal controls over financial reporting before their departure.
- Market Uncertainties and Client Budget Reductions: The company's financial performance is susceptible to broader market uncertainties within the pharmaceutical and biotechnology sectors. Simulations Plus reduced its fiscal 2025 revenue guidance, citing "significant headwinds" such as market uncertainties related to funding, drug pricing, and potential tariffs. These factors have led to budget reductions, project cancellations, and delays among its client base. While the software segment has shown resilience, the services arm, which contributes a significant portion of revenue, has proven more sensitive to this market volatility. The company has also experienced declining operating and net margins.
- Competitive Landscape and Niche Market Growth: Simulations Plus operates in a competitive healthcare software industry, facing rivals that are sometimes significantly larger. Although the company possesses industry-leading physiologically-based pharmacokinetic (PBPK) modeling tools and high recurring revenue from its software subscriptions, its future growth is closely tied to successful cross-selling and strategic mergers and acquisitions within its niche market. The challenge lies in expanding beyond its specialized market to achieve broader growth, even as some clients actively cut budgets.
AI Analysis | Feedback
The emergence of integrated, AI-driven drug discovery and development platforms offered by major technology companies or well-funded biotechnology startups poses a clear emerging threat. These platforms leverage advanced artificial intelligence and machine learning algorithms to perform molecular property prediction, ADMET analysis, and complex PBPK/QSP simulations with potentially superior efficiency, integration, and predictive accuracy compared to Simulations Plus's specialized, modular software suite. Such integrated platforms could offer a more holistic and streamlined approach to drug development, potentially reducing the need for multiple, disparate simulation tools and challenging the market for specialized software products.
AI Analysis | Feedback
Simulations Plus, Inc. (SLP) operates within several significant addressable markets related to drug discovery and development. These markets encompass software, artificial intelligence (AI), and services for modeling, simulation, and prediction of molecular properties. The global artificial intelligence (AI) in drug discovery market was valued at approximately USD 1.86 billion in 2024 and is projected to reach USD 6.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 29.9% from 2024 to 2029. North America held a 44.8% revenue share in this market in 2023. Other estimates place the global AI in drug discovery market at USD 2.09 billion in 2024, expected to reach USD 18.63 billion by 2032, with a CAGR of 31.48% from 2025 to 2032. North America is expected to remain a dominant force in this market, holding a 50% share in 2024. The global in-silico drug discovery market was valued at USD 2,829.7 million in 2023 and is predicted to reach USD 5,691.4 million by 2030, with a CAGR of 10.6% from 2024 to 2030. North America accounted for approximately 50% of this market in 2023. Another report indicates the global in-silico drug discovery market was valued at USD 4.737 billion in 2024 and is projected to reach USD 15.31 billion by 2035, growing at a CAGR of 11.25% from 2025 to 2035. North America led this market with over 44.33% share in 2024. The global drug discovery biosimulation software market was valued at USD 931 million in 2024 and is projected to grow to USD 2.04 billion by 2032, exhibiting a CAGR of 12.0% during the forecast period. North America currently holds over 45% of the revenue share in this market. The global pharmacometric modeling and simulation market reached USD 1.42 billion in 2024 and is poised to grow to USD 4.19 billion by 2033, at a CAGR of 12.7%. North America dominated the pharmacokinetics services market, accounting for 37.3% of revenue share in 2024. The global pharmacokinetics services market size was estimated at USD 1.15 billion in 2024 and is projected to reach USD 1.76 billion by 2030, growing at a CAGR of 7.4% from 2025 to 2030. The global drug modeling software market is projected to reach US$ 17.14 billion by 2031 from US$ 7.96 billion in 2023, registering a CAGR of 10.1% from 2023 to 2031. The global pharma ADMET testing market size is expected to reach US$ 24.80 billion by 2034 from US$ 10.10 billion in 2025, anticipating a CAGR of 10.49% from 2026 to 2034. North America is expected to dominate this market. The global ADME toxicology testing market size was estimated at USD 6.38 billion in 2024 and is projected to witness a CAGR of 10.0% from 2025 to 2030. The broader life science software market was valued at USD 22,224.18 million (approximately USD 22.22 billion) in 2024 and is expected to increase to USD 51,640.39 million (approximately USD 51.64 billion) by 2031, growing at a CAGR of 12.8%. North America captured a major revenue share of 42% of the life science software market in 2025. Within this, the research & drug discovery segment dominated by 30% in 2025.AI Analysis | Feedback
Expected Drivers of Future Revenue Growth for Simulations Plus (SLP)
Simulations Plus (SLP) is positioned for future revenue growth over the next 2-3 years, driven by several strategic initiatives and favorable market dynamics:
- Integrated, AI-Enabled Modeling Ecosystem: The company is focused on developing an integrated, AI-enabled modeling ecosystem that spans drug discovery, development, clinical operations, and commercialization. This strategy combines validated science with cloud-scale performance and AI, aiming to deliver new capabilities to the market faster and with greater cohesion. This unified product and technology strategy, including AI-driven workflows and AI-accelerated drug development, is central to their growth plans.
- Growth in the Services Segment: Simulations Plus has demonstrated strong performance in its services segment, with a 16% increase in Q1 2026 revenue and an 18% increase in the services backlog. The company anticipates that the improvement in services revenue and robust pipeline will precede and contribute to an increase in software activity, thereby driving future overall revenue growth.
- Annual Software Price Increases: Management has indicated that annual software price increases will contribute to achieving their fiscal year 2026 guidance, suggesting this will be an ongoing factor in revenue growth.
- Enhanced Cross-Selling through Sales Reorganization: Simulations Plus is restructuring its sales strategy by shifting from a product-focused model to one based on geographical and account ownership. This reorganization is designed to optimize cross-selling opportunities across its diverse product portfolio, which is expected to boost revenue generation.
- Accelerating Adoption of Model-Informed Drug Development (MIDD) and AI: The biopharmaceutical industry is undergoing a transformation, with companies increasingly prioritizing predictability, transparency, and scientific rigor in drug development. This shift is leading to an accelerating adoption of model-informed drug development (MIDD) and AI, creating a strong market demand for Simulations Plus's innovative solutions.
AI Analysis | Feedback
Share Repurchases
- Simulations Plus announced a share repurchase program authorizing up to $50 million of its common stock on January 4, 2023.
- On January 12, 2023, the company executed an accelerated share repurchase (ASR) agreement totaling $20 million.
- Following the $20 million ASR, $30 million remained available under the previously authorized share repurchase program.
Share Issuance
- Simulations Plus Chief Revenue Officer exercised fully vested stock options for 10,300 shares of common stock on February 6, 2026.
- An equity award of 1,776 shares of common stock was granted to independent directors on January 30, 2026, under the company's 2021 Equity Incentive Plan.
- The number of shares outstanding has generally remained around 20-21 million from late 2020 through late 2025.
Outbound Investments
- Simulations Plus acquired Pro-ficiency Holdings, Inc. and its subsidiaries in June 2024 to extend its reach across the drug development value chain.
Capital Expenditures
- Capital expenditures for the last 12 months (as of early March 2026) were approximately $627,000.
- The company reported $0 in capital expenditures in Q1 2026.
Latest Trefis Analyses
Trade Ideas
Select ideas related to SLP.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 08312022 | SLP | Simulations Plus | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | -36.1% | -25.5% | -41.7% |
| 08312020 | SLP | Simulations Plus | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 22.8% | -25.4% | -29.2% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 14.91 |
| Mkt Cap | 1.0 |
| Rev LTM | 337 |
| Op Inc LTM | 16 |
| FCF LTM | -64 |
| FCF 3Y Avg | 40 |
| CFO LTM | 60 |
| CFO 3Y Avg | 52 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.6% |
| Rev Chg 3Y Avg | 14.1% |
| Rev Chg Q | 0.8% |
| QoQ Delta Rev Chg LTM | 0.2% |
| Op Inc Chg LTM | 28.4% |
| Op Inc Chg 3Y Avg | 29.0% |
| Op Mgn LTM | 5.9% |
| Op Mgn 3Y Avg | 6.4% |
| QoQ Delta Op Mgn LTM | -0.1% |
| CFO/Rev LTM | 12.4% |
| CFO/Rev 3Y Avg | 16.8% |
| FCF/Rev LTM | 7.1% |
| FCF/Rev 3Y Avg | 12.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 1.0 |
| P/S | 4.0 |
| P/Op Inc | 26.3 |
| P/EBIT | 18.1 |
| P/E | -3.0 |
| P/CFO | 12.1 |
| Total Yield | -5.4% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 3.3% |
| D/E | 0.2 |
| Net D/E | -0.0 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 12.6% |
| 3M Rtn | -4.4% |
| 6M Rtn | -22.1% |
| 12M Rtn | -37.1% |
| 3Y Rtn | -55.4% |
| 1M Excs Rtn | 4.3% |
| 3M Excs Rtn | -11.1% |
| 6M Excs Rtn | -35.3% |
| 12M Excs Rtn | -67.7% |
| 3Y Excs Rtn | -137.7% |
Comparison Analyses
Price Behavior
Price Behavior
| Market Price | $16.68 | |
| Market Cap ($ Bil) | 0.3 | |
| First Trading Date | 06/19/1997 | |
| Distance from 52W High | -49.5% | |
| 50 Days | 200 Days | |
| DMA Price | $13.19 | $15.44 |
| DMA Trend | down | down |
| Distance from DMA | 26.5% | 8.0% |
| 3M | 1YR | |
| Volatility | 46.9% | 62.5% |
| Downside Capture | 0.29 | 0.86 |
| Upside Capture | 107.31 | 47.34 |
| Correlation (SPY) | 36.6% | 23.5% |
SLP Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.33 | 1.13 | 1.45 | 1.22 | 1.26 | 0.91 |
| Up Beta | 1.15 | 1.34 | 1.54 | 1.31 | 1.25 | 1.01 |
| Down Beta | 1.29 | 0.76 | 0.47 | 0.07 | 1.11 | 0.29 |
| Up Capture | 190% | 157% | 107% | 128% | 43% | 60% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 16 | 24 | 32 | 63 | 120 | 357 |
| Down Capture | -42% | 71% | 207% | 163% | 164% | 109% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 6 | 19 | 32 | 62 | 129 | 389 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLP | |
|---|---|---|---|---|
| SLP | -37.3% | 61.9% | -0.50 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 15.6% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 23.9% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 1.8% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -2.2% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 13.8% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 29.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLP | |
|---|---|---|---|---|
| SLP | -20.8% | 50.7% | -0.27 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 28.6% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 34.7% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 5.2% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 6.0% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 31.0% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 22.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SLP | |
|---|---|---|---|---|
| SLP | 9.3% | 48.1% | 0.37 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 31.5% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 34.7% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 5.1% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 8.7% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 26.5% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 14.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/9/2026 | 0.4% | 8.7% | 28.4% |
| 1/8/2026 | 8.6% | 12.2% | -21.9% |
| 10/22/2025 | 13.2% | 17.7% | 4.9% |
| 7/14/2025 | -25.8% | -24.8% | -18.8% |
| 4/3/2025 | 7.8% | 8.1% | 41.1% |
| 1/7/2025 | -7.2% | -1.8% | 19.4% |
| 10/23/2024 | -8.9% | -15.6% | -11.6% |
| 7/2/2024 | -14.9% | -18.0% | -14.5% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 9 |
| # Negative | 10 | 9 | 11 |
| Median Positive | 7.8% | 8.1% | 22.7% |
| Median Negative | -11.7% | -14.3% | -11.4% |
| Max Positive | 13.2% | 19.7% | 41.1% |
| Max Negative | -25.8% | -24.8% | -21.9% |
Recent Forward Guidance [BETA]
Latest: Q2 2026 Earnings Reported 4/9/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 79.00 Mil | 80.50 Mil | 82.00 Mil | 0 | Affirmed | Guidance: 80.50 Mil for 2026 | |
| 2026 Revenue Growth | 0.0% | 2.0% | 4.0% | 0 | 0 | Affirmed | Guidance: 2.0% for 2026 |
| 2026 Software mix | 0.57 | 0.59 | 0.62 | 0 | Affirmed | Guidance: 0.59 for 2026 | |
| 2026 Adjusted EBITDA margin | 26.0% | 28.0% | 30.0% | 0 | 0 | Affirmed | Guidance: 28.0% for 2026 |
| 2026 Adjusted diluted EPS | 0.75 | 0.8 | 0.85 | -24.9% | Lowered | Guidance: 1.06 for 2026 | |
Prior: Q1 2026 Earnings Reported 1/8/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 79.00 Mil | 80.50 Mil | 82.00 Mil | 0 | Affirmed | Guidance: 80.50 Mil for 2026 | |
| 2026 Revenue Growth | 0.0% | 2.0% | 4.0% | 0 | 0 | Affirmed | Guidance: 2.0% for 2026 |
| 2026 Software mix | 0.57 | 0.59 | 0.62 | 0 | Affirmed | Guidance: 0.59 for 2026 | |
| 2026 Adjusted EBITDA margin | 26.0% | 28.0% | 30.0% | 0 | 0 | Affirmed | Guidance: 28.0% for 2026 |
| 2026 Adjusted diluted EPS | 1.03 | 1.06 | 1.1 | 0 | Affirmed | Guidance: 1.06 for 2026 | |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Dibella, John Anthony II | Chief Revenue Officer | Direct | Sell | 5052026 | 14.98 | 1,000 | 14,980 | 1,320,337 | Form |
| 2 | Woltosz, Walter S | Direct | Sell | 5052026 | 15.13 | 15,000 | 226,950 | 49,441,814 | Form | |
| 3 | Dibella, John Anthony II | Chief Revenue Officer | Direct | Sell | 4162026 | 13.37 | 1,000 | 13,370 | 1,191,802 | Form |
| 4 | Lavange, Lisa | Direct | Sell | 12022025 | 16.91 | 866 | 14,644 | 168,559 | Form | |
| 5 | Woltosz, Walter S | Direct | Sell | 10032025 | 15.39 | 20,000 | 307,800 | 50,575,095 | Form |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.